Ananta Addala1, David M Maahs1,2, David Scheinker1,2,3, Solana Chertow4, Brianna Leverenz1, Priya Prahalad1. 1. Division of Pediatric Endocrinology, Stanford University, Stanford, California, USA. 2. Stanford Diabetes Research Center, Stanford University, Stanford, California, USA. 3. Department of Management Science and Engineering, Stanford University, Stanford, California, USA. 4. School of Arts and Sciences, Washington University in St. Louis, St. Louis, Missouri, USA.
Abstract
OBJECTIVE: Continuous glucose monitor (CGM) use is associated with improved glucose control. We describe the effect of continued and interrupted CGM use on hemoglobin A1c (HbA1c) in youth with public insurance. METHODS: We reviewed 956 visits from 264 youth with type 1 diabetes (T1D) and public insurance. Demographic data, HbA1c and two-week CGM data were collected. Youth were classified as never user, consistent user, insurance discontinuer, and self-discontinuer. Visits were categorized as never-user visit, visit before CGM start, visit after CGM start, visit with continued CGM use, visit with initial loss of CGM, visit with continued loss of CGM, and visit where CGM is regained after loss. Multivariate regression adjusting for age, sex, race, diabetes duration, initial HbA1c, and body mass index were used to calculate adjusted mean and delta HbA1c. RESULTS: Adjusted mean HbA1c was lowest for the consistent user group (HbA1c 8.6%;[95%CI 7.9,9.3]). Delta HbA1c (calculated from visit before CGM start) was lower for visit after CGM start (-0.39%;[95%CI -0.78,-0.02]) and visit with continued CGM use (-0.29%;[95%CI -0.61,0.02]), whereas it was higher for visit with initial loss of CGM (0.40%;[95%CI -0.06,0.86]), visit with continued loss of CGM (0.46%;[95%CI 0.06,0.85]), and visit where CGM is regained after loss (0.57%;[95%CI 0.06,1.10]). CONCLUSIONS: Youth with public insurance using CGM have improved HbA1c, but only when CGM use is uninterrupted. Interruptions in use, primarily due to gaps in insurance coverage of CGM, were associated with increased HbA1c. These data support both initial and ongoing coverage of CGM for youth with T1D and public insurance.
OBJECTIVE: Continuous glucose monitor (CGM) use is associated with improved glucose control. We describe the effect of continued and interrupted CGM use on hemoglobin A1c (HbA1c) in youth with public insurance. METHODS: We reviewed 956 visits from 264 youth with type 1 diabetes (T1D) and public insurance. Demographic data, HbA1c and two-week CGM data were collected. Youth were classified as never user, consistent user, insurance discontinuer, and self-discontinuer. Visits were categorized as never-user visit, visit before CGM start, visit after CGM start, visit with continued CGM use, visit with initial loss of CGM, visit with continued loss of CGM, and visit where CGM is regained after loss. Multivariate regression adjusting for age, sex, race, diabetes duration, initial HbA1c, and body mass index were used to calculate adjusted mean and delta HbA1c. RESULTS: Adjusted mean HbA1c was lowest for the consistent user group (HbA1c 8.6%;[95%CI 7.9,9.3]). Delta HbA1c (calculated from visit before CGM start) was lower for visit after CGM start (-0.39%;[95%CI -0.78,-0.02]) and visit with continued CGM use (-0.29%;[95%CI -0.61,0.02]), whereas it was higher for visit with initial loss of CGM (0.40%;[95%CI -0.06,0.86]), visit with continued loss of CGM (0.46%;[95%CI 0.06,0.85]), and visit where CGM is regained after loss (0.57%;[95%CI 0.06,1.10]). CONCLUSIONS: Youth with public insurance using CGM have improved HbA1c, but only when CGM use is uninterrupted. Interruptions in use, primarily due to gaps in insurance coverage of CGM, were associated with increased HbA1c. These data support both initial and ongoing coverage of CGM for youth with T1D and public insurance.
Authors: Molly L Tanenbaum; Laurel H Messer; Christine A Wu; Marina Basina; Bruce A Buckingham; Danielle Hessler; Shelagh A Mulvaney; David M Maahs; Korey K Hood Journal: Diabetes Res Clin Pract Date: 2021-09-14 Impact factor: 8.180
Authors: Karishma A Datye; Daniel R Tilden; Angelee M Parmar; Eveline R Goethals; Sarah S Jaser Journal: Curr Diab Rep Date: 2021-05-15 Impact factor: 4.810
Authors: David Tsai; Jaquelin Flores Garcia; Jennifer L Fogel; Choo Phei Wee; Mark W Reid; Jennifer K Raymond Journal: J Diabetes Sci Technol Date: 2021-07-05
Authors: Molly L Tanenbaum; Jessica Ngo; Sarah J Hanes; Marina Basina; Bruce A Buckingham; Danielle Hessler; David M Maahs; Shelagh Mulvaney; Korey K Hood Journal: Diabetes Technol Ther Date: 2021-12 Impact factor: 6.118